Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19-Reference-Cited by-同舟云学术

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

Published:2022-06-28 Issue:3 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Zhao Wei¹,Chen Weixin¹,Li Juan¹^ORCID,Chen Meng¹,Li Qin²,Lv Min¹,Zhou ShanShan¹,Bai Shuang¹,Wang Yali¹,Zhang Lichi¹,Zhang Peng¹,Wang Jian¹,Zheng Qun³^ORCID,Wu Jiang¹

Affiliation:

1. Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing, China

2. Department of Laboratory, Yanjing Medical College, Capital Medical University, Beijing, China

3. Experimental Center for Basic Medical Teaching, School of Basic Medical Sciences, Capital Medical University, Beijing, China

Abstract

CoronaVac is an inactivated vaccine containing whole-virion SARS-CoV-2, which has been approved in 43 countries for emergency use as of 26 November 2021. However, the long-term immune persistence of the CoronaVac vaccine is still unknown. Here, we reported the status of the persistence of antibodies and cellular responses within 12 months after two doses of CoronaVac. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.

Funder

Beijing Municipal Science & Technology Commission

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.00181-22

Reference41 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. UNIECF. 2021. COVID-19 vaccine market dashboard. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard. Accessed 8 October 2021.

3. Ritchie H Mathieu E Rodés-Guirao L Appel C Giattino C Ortiz-Ospina E Hasell J Macdonald B Beltekian D Roser M. 2021. Coronavirus (COVID-19) vaccinations. https://ourworldindata.org/covid-vaccinations. Accessed 8 October 2021.

4. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

5. WHO. 2021. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO interim recommendations for use of the inactivated COVID-19 vaccine CoronaVac developed by Sinovac. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time-resolved scRNA-seq reveals transcription dynamics of polarized macrophages with influenza A virus infection and antigen presentation to T cells;Emerging Microbes & Infections;2024-09

2. Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study;Frontiers in Immunology;2024-08-20

3. A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection;Vaccines;2024-05-18

4. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice;Viral Immunology;2023-10-01

5. Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project;Vaccines;2023-09-26